Harrow

Planning to attend the AAO 2024 Conference in Chicago, IL? Come visit us at booth #3844 to learn more about Harrow and our product offerings. #harrow #AAO2024 #ophthalmology #visitus

October is Blindness Awareness Month. Throughout this month, we celebrate the achievements of individuals who are blind or have visual disabilities, showcasing their resilience and contributions. By raising awareness, we can promote inclusivity and empower individuals with vision loss, ensuring they receive the resources and respect they deserve. #Harrow #VisionLoss #blindnessawareness

We are bringing TRIESENCE (triamcinolone acetonide injectable suspension) 40mg/mL back! Be the first to know when it’s available by signing up at: https://lnkd.in/eW7w-rpd

Harrow is excited to bring TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL back to the U.S. market! Following five years on the FDA Drug Shortage List and being out of stock for the last two years, this trusted FDA-approved corticosteroid is once again available for visualization during vitrectomy and treating ocular inflammatory conditions that don't respond to topical treatments. Harrow CEO Mark L. Baum said, "The return of TRIESENCE to the market is a significant milestone for Harrow and for the many eyecare professionals who have long relied on this important product. We are extremely grateful to the Harrow Family and our manufacturing partners for their dedication to making this happen. We’re proud to be delivering on our mission to improve the quality of care for millions of patients.” Healthcare providers may order TRIESENCE directly through major pharmaceutical specialty distributors, including Besse Medical/Cencora, McKesson Medical-Surgical, and Cardinal Health. Initial supplies of TRIESENCE will be listed under both NDC 00078-0897-78 and NDC 82667-800-01. #Harrow #TRIESENCE #Ophthalmology #EyeCare #Pharmaceuticals https://lnkd.in/eJ7urvH4

September marked Healthy Aging Month. Throughout this month, we encourage you to dedicate attention to your eye health. As we celebrate aging with grace, let's ensure that we prioritize our vision and eye care! #Harrow #HealthyAgingMonth #Wellness #EyeHealth

✨ PHOTO RECAP ✨ We were honored to join the Harrow team and Metro Nashville Mayor Freddie O'Connell this morning at the company's $3 million expansion announcement. Nashville has the potential to become the nation’s epicenter for healthcare, and we are one step closer thanks to continued investment like this. 🙌 Learn more: https://lnkd.in/gHTTbkrE

Have you signed up to be the first to know when it’s available? Visit this link to be in the know: https://lnkd.in/eW7w-rpd

We’re proud to share that Harrow is continuing to build a dynamic and high-performing pharmaceutical sales team, attracting top-tier talent to drive our growth and innovation in the eye care industry. Our latest exciting addition is Alyson Harrison, MBA, CCOA , who joins Harrow as Vice President, Posterior Portfolio, with responsibility for IHEEZO and TRIESENCE. With over two decades of experience, including her most recent role as Director of GPO & Key Accounts at Regeneron, Aly brings a deep understanding of hospital sales, Buy & Bill biologics, and GPO leadership. She has established strong relationships with key opinion leaders nationwide and successfully led teams focused on retina diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME). At Harrow, we’re committed to fostering a culture where the best minds can thrive, collaborate, and push boundaries. We are thrilled to welcome Aly to the team and can’t wait to see the impact she’ll make! #Harrow #Growth #Teamwork #Innovation #Leadership #Ophthalmology #Hiring

Harrow CEO, Mark Baum, and CFO, Andrew Boll, will be participating in the 2024 Cantor Global Healthcare Conference in New York, September 17-19. We’re looking forward to engaging with industry leaders, discussing healthcare innovation, and sharing insights on Harrow’s growth and vision for the future. Join us in New York as we continue to drive advancements in ophthalmology and provide solutions that positively impact patients' lives. #Harrow #IHEEZO #VEVYE #TRIESENCE #Ophthalmology #Innovation #Leadership #eyecare

Something bright is on the horizon…TRIESENCE (triamcinolone acetonide injectable suspension) 40mg/mL! Be the first to know when it’s available by signing up at: https://lnkd.in/eW7w-rpd